Mesoblast
(ASX:MSB) has reported a further dive into negative territory with its attributable loss falling to US$76.8 million in the 2017 financial year.
The regenerative medicine company’s revenue was not as great as 2016, falling from US$42.6 million to US$2.4 million for 12 months to 30 June.
Its cash reserves at the end of the financial year hit US$45.8 million. The business plans to use its cash reserves to progress its acute graft versus host disease trials.
The company did not declare a dividend for the year.
Shares in Mesoblast
(ASX:MSB) closed 11.8 per cent lower yesterday to $1.42.
